Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIM-DJ2727 in Severe Alcoholic Hepatitis
NCT05006430Phase 2Recruiting
- Start
- Jan 2023
- Primary completion
- Jun 2025
- Modality
- Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of PRIM-DJ2727 in alcoholic hepatitis (AH) (2 arms). Primary endpoints: Survival at 12 months and Gut microbiome population at 12 months. Started Jan 2023; status: recruiting.
02
Drugs
PRIM-DJ2727
03
Conditions
alcoholic hepatitis (AH)
Beyond the preview
Go deeper on NCT05006430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05006430.